Glaukos price target raised to $130 from $120 at Citi

Citi raised the firm’s price target on Glaukos to $130 from $120 and keeps a Buy rating on the shares. The firm says the Q1 earnings season volatility creates opportunity in the medical technology space. The U.S. hospital capital purchasing environment is stable and China remains a point of volatility through anti-corruption policies and stimulus packages, the analyst tells investors in a research note. Citi left Boston Scientific (BSX) as a top pick while removing Irhythm Technologies (IRTC) and Intuitive Surgical (ISRG). The firm also added GE HealthCare (GEHC) as it recovers from a Q1 low and Insulet (PODD) as it expects a stronger second half of 2024 and momentum into 2025.